NCT06635798
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection No drug interventions prevention 3 recruiting NCT06618196
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age No drug interventions prevention 2 not_yet_recruiting NCT06605755
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants No drug interventions prevention Not Available recruiting NCT06607380
A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine No drug interventions treatment 1 completed NCT06588530
PFAS Exposure and Immune Response to Vaccination in Adults basic_science 4 not_yet_recruiting NCT01031303
Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age prevention 4 completed NCT02422264
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery prevention 4 completed NCT00355121
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® prevention 2 completed NCT00343421
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers prevention 3 completed NCT00255021
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand prevention 4 completed NCT01248884
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) prevention 2 completed NCT02569879
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. No drug interventions Not Available Not Available completed NCT01470287
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age No drug interventions prevention 3 completed NCT01491087
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China prevention 4 completed NCT00534833
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ prevention 3 completed NCT02094833
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants prevention 3 completed NCT02817451
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants prevention 3 completed NCT06120751
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over No drug interventions prevention 3 recruiting NCT00319553
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® prevention 4 completed NCT01738477
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults prevention 3 completed NCT05625477
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers prevention 2 completed NCT01062477
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants prevention 3 completed NCT00316147
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules prevention 3 completed NCT00168545
Immunology of Non-specific Effects of Vaccine diagnostic 4 completed NCT02257645
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks No drug interventions Not Available Not Available unknown_status NCT01294605
Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) prevention 4 completed NCT01277705
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® prevention 3 completed NCT01559597
Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain prevention Not Available completed NCT01249183
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old prevention 3 completed NCT02458183
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS No drug interventions prevention 3 completed NCT03870061
Evaluation of an Infant Immunization Encouragement Program in Nigeria No drug interventions prevention Not Available completed NCT02118961
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents prevention 3 completed NCT00337428
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) No drug interventions prevention 3 completed NCT00964028
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) prevention 3 completed NCT04165928
Multicenter Study of Tetanus Patients in Fujian Province of China No drug interventions Not Available Not Available completed NCT04056728
A Phase IV Study to Assess the Safety of EupentaTM Inj No drug interventions prevention 4 unknown_status NCT00635128
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine prevention 4 completed NCT02538211
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses prevention Not Available completed NCT06034093
Real-time Artificial Intelligent (AI)-Assisted Muscle Ultrasound for Monitoring Muscle Mass Reduction in ICU Patients No drug interventions supportive_care Not Available completed NCT00544271
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines. prevention 4 terminated NCT00437671
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels prevention 4 terminated NCT01546909
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE No drug interventions prevention 4 completed NCT02274285
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants No drug interventions prevention 3 completed NCT02999815
Intrathecal Tetanus Immunoglobulin to Treat Tetanus No drug interventions treatment 1 / 2 completed NCT00835237
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. prevention 3 completed NCT00319852
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV prevention 3 completed NCT01040052
A Study to Assess the Safety of Adacel® Vaccine prevention 3 completed NCT01331252
Pneumonia in Tetanus Study No drug interventions supportive_care Not Available completed NCT00712959
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose prevention 4 completed NCT00611559
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children prevention 4 completed NCT04073459
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants No drug interventions prevention 2 unknown_status NCT01323959
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults No drug interventions prevention 4 completed NCT00453570
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months prevention 3 completed NCT00662870
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine prevention 3 completed NCT00432042
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) prevention 3 completed NCT06184542
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine prevention 1 recruiting NCT00290342
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants prevention 3 completed NCT00457249
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older prevention 4 completed NCT00753649
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants prevention 4 completed NCT02040636
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis prevention 2 completed NCT00467519
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age prevention 3 completed NCT00871741
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. prevention 2 terminated NCT00228917
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children prevention 3 completed NCT00303316
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants prevention 3 completed NCT01659996
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age prevention 4 completed NCT01267058
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults prevention 3 completed NCT00347958
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine prevention 4 completed NCT03891758
Confirmatory Study of BK1310 in Healthy Infants prevention 3 completed NCT00601835
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td prevention 4 completed NCT00146835
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine Not Available Not Available completed NCT00320463
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants prevention 3 completed NCT00352963
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). No drug interventions prevention 3 completed NCT00452686
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine prevention 3 completed NCT04618939
To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children No drug interventions prevention 3 completed NCT03931239
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks No drug interventions prevention Not Available completed NCT01177722
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants prevention 3 completed NCT01362322
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents prevention 4 completed NCT01358825
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ No drug interventions prevention 4 completed NCT00447525
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children prevention 3 completed NCT00707148
Pertussis Vaccine in Healthy Pregnant Women prevention 1 completed NCT01311557
Study of Adacel® Vaccine Administered to Persons 10 Years of Age prevention 4 completed NCT00777257
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine prevention 4 completed NCT01988857
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children prevention 3 completed NCT00332566
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib prevention 3 completed NCT00304265
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine No drug interventions prevention 4 completed NCT01357720
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination No drug interventions prevention 4 completed NCT01810731
Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya prevention 2 / 3 withdrawn NCT00346073
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years prevention 3 completed NCT00879827
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants prevention 3 completed NCT01933776
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China prevention 1 completed NCT01568060
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea No drug interventions Not Available Not Available completed NCT05480462
Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. No drug interventions prevention 3 active_not_recruiting NCT00316680
Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age. prevention 3 terminated NCT00518180
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents No drug interventions prevention 3 completed NCT03128489
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants prevention 3 withdrawn NCT01171989
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose prevention 2 completed NCT01629589
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents prevention 4 completed NCT00343889
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine prevention 3 completed NCT00287092
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants prevention 3 completed NCT02858440
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia prevention 3 completed NCT06049940
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population No drug interventions prevention 3 completed NCT00802867
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ prevention 4 completed NCT00291967
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants No drug interventions prevention 2 completed NCT00307567
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 No drug interventions prevention 2 completed NCT00654901
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ prevention 3 completed NCT00136604
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m prevention 3 completed NCT00610168
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. prevention 4 completed NCT00473668
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib prevention 3 completed NCT00932269
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease No drug interventions Not Available Not Available unknown_status NCT00254969
Immunogenicity and Safety of Pentaxim in South African Infants prevention 3 completed NCT01309646
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine prevention 3 completed NCT05457946
Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series No drug interventions prevention 2 / 3 not_yet_recruiting NCT00617812
Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine No drug interventions prevention 4 completed NCT00348881
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants No drug interventions prevention 3 completed NCT00282295
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease prevention 4 completed NCT00258895
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® prevention 3 completed NCT00855855
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease Not Available Not Available completed NCT00385255
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults prevention 3 completed NCT01890850
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants No drug interventions Not Available Not Available completed NCT05664750
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus treatment 3 completed NCT00870350
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster No drug interventions basic_science 4 unknown_status NCT01086423
Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine prevention 3 completed NCT00258908
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan prevention 3 completed NCT00158808
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths prevention 2 completed NCT00674908
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine No drug interventions prevention 4 completed NCT01457508
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately prevention 3 completed NCT00325143
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine prevention 3 completed NCT00290303
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants No drug interventions prevention 3 completed NCT04099303
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . prevention 1 completed NCT01353703
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine prevention 3 completed NCT00804284
Database Surveillance Safety Study of PENTACEL® Vaccine Not Available Not Available completed NCT00376779
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age prevention 2 completed NCT00263679
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. No drug interventions prevention 3 completed NCT00317187
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. prevention 3 completed NCT00412854
Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. prevention 3 completed NCT00404651
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants prevention 3 completed NCT01090453
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants prevention 2 completed NCT00831753
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants prevention 3 completed NCT00379977
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age No drug interventions prevention 3 completed NCT01457547
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course prevention 4 completed NCT02089347
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old prevention 3 completed NCT00133445
Pentavalent DTaP-Hep B-IPV No drug interventions prevention 2 completed NCT01529645
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years prevention 1 completed NCT01711645
Tdap Vaccine in Post-Partum Women prevention 4 completed NCT03552445
Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine No drug interventions prevention 4 completed NCT01453998
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) prevention 2 completed NCT04142983
Tdap Vaccine Safety for Plasma Donors prevention 2 / 3 completed NCT00317161
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. No drug interventions prevention 3 completed NCT00772928
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ prevention 3 completed NCT03266211
Antitetanus Vaccination for People Older Than 65 Years. No drug interventions Not Available Not Available completed NCT00831311
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants prevention 2 completed NCT00797511
Immunogenicity and Safety of Adacel Polio Vaccine prevention 3 completed NCT00313911
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. prevention 3 completed NCT01948193
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth prevention 3 completed NCT01346293
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age prevention 3 completed NCT00548171
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 prevention 4 completed NCT02447978
Duration of Protection: GSK DTaP Vaccines Not Available Not Available completed NCT01338688
The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td No drug interventions Not Available Not Available completed NCT00970307
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age prevention 2 completed NCT00514709
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants prevention 3 completed NCT00325156
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants prevention 4 completed NCT00297856
Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine Not Available Not Available completed NCT04177485
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda No drug interventions prevention Not Available completed NCT00908115
Post Market Surveillance for Infanrix™ Not Available Not Available completed NCT00259337
Immunogenicity and Safety of Pentaxim™ in an Indian Population prevention 3 completed NCT00463437
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines prevention 3 completed NCT01577732
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers prevention 3 completed NCT00871000
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. prevention 3 completed NCT01147900
Evaluation of Boostrix™10 Years After Previous Booster Vaccination prevention 4 completed NCT01105559
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine No drug interventions Not Available Not Available completed NCT00514059
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine No drug interventions prevention 4 completed NCT00197275
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants No drug interventions prevention 3 completed NCT04238975
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults prevention 2 unknown_status NCT00489970
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 prevention 3 completed NCT00169442
Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants prevention 3 completed NCT01245049
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children prevention 3 completed NCT01287949
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older prevention 3 completed NCT05091619
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed prevention 3 active_not_recruiting NCT00148941
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines prevention 3 completed NCT00871117
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years prevention 3 completed NCT00254917
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines prevention 4 completed NCT01362517
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B No drug interventions treatment 3 completed NCT01689324
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents prevention 1 / 2 completed NCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults No drug interventions prevention 1 not_yet_recruiting NCT00627458
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine prevention 2 completed NCT01137435
Post Marketing Surveillance for ADACEL™ in South Korea prevention 4 completed NCT00317135
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. prevention 3 completed NCT01878435
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya No drug interventions other Not Available completed NCT02096263
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants prevention 3 completed NCT06123663
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over No drug interventions prevention 1 active_not_recruiting NCT02813486
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine prevention 1 / 2 unknown_status NCT03950986
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System No drug interventions prevention Not Available completed NCT00325130
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) prevention 3 completed NCT00109330
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine prevention 3 completed NCT00877357
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine No drug interventions prevention 4 unknown_status NCT01917357
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject No drug interventions prevention 3 completed NCT01439165
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose prevention 4 completed NCT06302374
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults treatment 1 / 2 completed NCT00317174
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. No drug interventions prevention 2 completed NCT02587520
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects prevention 1 / 2 completed NCT01003431
A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) prevention 3 withdrawn NCT01993173
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. prevention 3 completed NCT00362427
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® prevention 2 completed NCT01457560
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine prevention 3 completed NCT02428491
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth prevention 3 completed NCT00406562
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. prevention 3 completed NCT02853929
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery prevention 4 completed NCT01214889
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. prevention 3 completed NCT00263692
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety No drug interventions prevention 2 completed NCT01106092
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers No drug interventions prevention 2 completed NCT04618640
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years No drug interventions prevention 3 unknown_status NCT01983540
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination prevention 3 completed NCT03208101
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults No drug interventions prevention 1 completed NCT00138268
Pilot Study Freeze and Transport Immune Cells No drug interventions Not Available Not Available completed NCT03589768
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants prevention 2 completed NCT00092469
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) prevention 3 completed NCT00772369
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children No drug interventions Not Available Not Available completed NCT01449812
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine prevention 3 completed NCT01444781
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants prevention 3 completed NCT01457495
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly prevention 2 completed NCT03341195
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan No drug interventions prevention Not Available unknown_status NCT06056050
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) No drug interventions prevention 1 recruiting NCT00696423
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children prevention 3 completed NCT01437423
Regulatory Post-Marketing Surveillance Study for TETRAXIM™ prevention 4 completed